Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASLAN Cuts Costs, Jobs And Refocuses After Varlitinib Setback

Executive Summary

Singapore-based company prioritizes resources and cuts jobs following the recent Phase II failure of its lead pipeline asset in first-line gastric cancer.

You may also be interested in...



Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

ASLAN, Sosei Pipeline Assets Hit By Development Delays

Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.

ASLAN's Downsized US IPO Off To A Slump Start

Singapore venture ASLAN's US IPO has got off to a disappointing start, with the shares in what was already a downsized offering falling sharply in early trading.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel